Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by V Square Quantitative Management LLC

V Square Quantitative Management LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 417.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,913 shares of the medical research company's stock after purchasing an additional 1,543 shares during the quarter. V Square Quantitative Management LLC's holdings in Thermo Fisher Scientific were worth $1,112,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. WCM Investment Management LLC boosted its stake in Thermo Fisher Scientific by 0.3% in the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company's stock worth $527,524,000 after purchasing an additional 2,928 shares during the period. Summa Corp. purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $418,000. Phoenix Holdings Ltd. lifted its stake in Thermo Fisher Scientific by 21.4% in the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company's stock worth $4,750,000 after acquiring an additional 1,654 shares in the last quarter. S. R. Schill & Associates boosted its position in Thermo Fisher Scientific by 106.3% during the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company's stock worth $816,000 after acquiring an additional 792 shares during the period. Finally, Check Capital Management Inc. CA acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $219,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded down $3.89 during midday trading on Tuesday, hitting $590.12. The company's stock had a trading volume of 1,131,156 shares, compared to its average volume of 1,516,959. The stock's 50 day simple moving average is $576.49 and its 200 day simple moving average is $545.39. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The stock has a market capitalization of $225.26 billion, a price-to-earnings ratio of 37.85, a PEG ratio of 2.47 and a beta of 0.80. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping analysts' consensus estimates of $4.70 by $0.41. The company had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a dividend of $0.39 per share. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific's payout ratio is presently 10.01%.

Analysts Set New Price Targets

A number of brokerages recently commented on TMO. JPMorgan Chase & Co. boosted their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research report on Thursday, April 25th. Raymond James upped their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an "outperform" rating in a research note on Thursday, February 1st. The Goldman Sachs Group lifted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a "buy" rating in a research report on Wednesday, April 10th. Barclays raised their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an "equal weight" rating in a research note on Thursday, April 25th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a "buy" rating in a research note on Thursday, April 25th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $607.35.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company's stock, valued at approximately $70,873,516.56. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares of the company's stock, valued at $7,430,359.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,873,516.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,000 shares of company stock worth $18,486,980. Company insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.